IP University to introduce quota for orphan children from 2025-26
Delhi's Guru Gobind Singh Indraprastha University (GGSIPU) has announced the introduction of a quota for orphan children in its academic programs for the 2025-26 session, an official statement said. The move that aims to provide inclusive education was approved by the university's Academic Council, and comes a year after it implemented a quota for single girl children, it said.
According to the proposal, an additional seat will be reserved in each university school and program for orphan applicants. These students will also be eligible for a full tuition fee waiver under the university's Economically Weaker Section (EWS) scheme.
Vice Chancellor Mahesh Verma stated, "The university aims to provide education to all, including orphan children who have been affected by the COVID-19 pandemic or due to other reasons." He added that the university will work to ensure these students also benefit from various government financial assistance schemes.
Detailed implementation guidelines will be uploaded to the university website soon. Several other key academic reforms were discussed at the academic council meeting, including a separate Ph.D. program for working professionals, lateral entry for MBA (Fire and Industrial Safety), and the introduction of Spanish and other foreign languages in certificate programs.
The university also plans to launch a five-year integrated BA-MA program in Philosophy, new four-year B.Ed Special Education programs in three disciplines, and a post-M.Sc Diploma in Radiological Physics. Plans were also announced to establish an "In-situ Center for Indian Knowledge System and Technology Innovation." Additionally, the Narela campus is set to become operational soon with the launch of an M.Sc in Microbiology and several diploma and certificate programs.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
20 hours ago
- Hindustan Times
IISER scientists pioneer affordable RNA sensors for fast detection of Covid-19, Zika
Researchers from the Indian Institute of Science Education and Research (IISER) Pune have developed an improved, low-cost diagnostic method to detect viral infections such as Covid-19 and Zika. The research, published in a scientific journal titled ACS Synthetic Biology on May 29, 2025, demonstrates a novel approach to enhancing the sensitivity and speed of RNA-based diagnostics using synthetic biology tools known as toehold switches. The core team behind the study includes Tanvi Kale, Rudvi Pednekar, and Professor Chaitanya Athale from IISER Pune's Department of Biology. The project was carried out in close collaboration with international partners—Dr Keith Pardee from the University of Toronto, Canada, and Dr Fernán Federici from Pontificia Universidad Católica de Chile. The initiative was funded by the Shastri Indo-Canadian Institute and the International Development Research Centre (IDRC), Canada, supporting its development as part of a global effort to make diagnostics more accessible. Toehold switches, which are synthetic RNA devices designed to detect specific sequences of viral RNA, function like molecular switches. When these biosensors come into contact with target RNA from viruses like SARS-CoV-2 or Zika, they activate a visible output—often a colour change—enabling straightforward detection. Thus, serving as a 'genetic device', said Chaitanya Athale, faculty member, IISER, Pune, who led the study. The IISER team enhanced this mechanism by engineering the RNA sensors with 'translational enhancers,' small genetic sequences that increase the output signal by boosting protein production. This not only shortens the detection time but also makes the signal more easily visible to the naked eye, improving the overall effectiveness of the test. What sets this diagnostic innovation apart is its simplicity and adaptability. The test can be formatted onto paper strips, making it a portable tool that can be used even outside laboratory settings. This is particularly critical in remote or underserved areas where access to conventional testing infrastructure is limited. Since the system relies on programmable RNA technology, the same platform can be quickly adapted to detect other viruses by simply reprogramming the toehold sequences, giving it a broad range of applications beyond Covid-19 and Zika.
Time of India
a day ago
- Time of India
IISER Pune team develops 20-min Covid, Zika test that doesn't need lab for results
1 2 3 Pune: A team of researchers from IISER, Pune, have developed a method to enhance sensitivity of RNA "biosensors", which, when mixed with viral samples of Covid or Zika, can produce a colour signal to indicate or rule out infection, within 20 minutes. The team said the boosting method can be used to create low-cost diagnostic devices that can be quickly transported to regions where there are few labs, personnel or specialized equipment to screen populations. Mass testing was a challenge during the Covid pandemic when scores of districts — especially during 2021's second wave — reported severe shortages of RT-PCR kits, considered the "gold-standard" for reliable Covid diagnoses. "But RT-PCR machines were not readily available and were centrally located," said Chaitanya Athale, who was part of the IISER team that developed the new method. "Plus, you needed someone to collect samples, run it on the machines and then interpret the results. That's when we saw the need for a low-cost and decentralized test that can be deployed in areas without advanced infrastructure," Athale said. In many viruses, genetic information is stored in the form of RNA, similar to what DNA is for humans. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like USDJPY đang đi lên không? IC Markets Đăng ký Undo Covid, Zika and Ebola are all RNA viruses. The IISER team developed a modified synthetic RNA sequence known as a 'toehold switch' in the lab, which reacts when it comes in contact with viral RNA to change colour —visible to the naked eye — on a small paper disc. With advances in technology, the team was able to reach detection limits of one picomolar (10 raised to -12). Picomolar is a unit of concentration commonly used to quantify a certain substance in a solution. "PCR, by comparison, is much more sensitive, but this method can be used by a minimally trained technician with test results landing in about 20 minutes," Athale said. RT-PCR test results may take a day or two to show, but the time also depends on how burdened a lab is. Currently, IISER's prototype test works only for Covid and Zika swab samples. A sample dropped onto two discs that will light up accordingly — one, both, or neither — depending on what's present. The test showed consistent results in IISER's lab in Pune and Chile, where partner scientists helped to develop the test. The Pune researchers said regulatory approvals and funding would be needed to take the test to clinics, where it can be tested further. "We've exhausted our grants, but we have manpower. Essentially, we have the people and hope to get the support," Athale said. Others who were part of the test's development team were Tanvi Kale and Rudvi Pednekar. The team's study published in ACS Synthetic Biology, was in collaboration with research teams of Dr Keith Pardee (University of Toronto, Canada) and Dr Fernán Federici (Pontificia Universidad Católica de Chile, Chile). Follow more information on Air India plane crash in Ahmedabad here . Get real-time live updates on rescue operations and check full list of passengers onboard AI 171 .
Time of India
a day ago
- Time of India
UAE scientists create paper test that diagnoses diseases in 10 mins, no lab needed!
UAE's 10-minute paper test can be quickly modified to detect COVID-19, malaria, dengue, chickenpox, and more/ Photo : Abu Dhabi Media Office A breakthrough in infectious disease testing is set to revolutionize the way healthcare is approached in low-resource and remote settings. A team of scientists at New York University Abu Dhabi (NYUAD) has unveiled a paper-based diagnostic tool, the Radially Compartmentalised Paper Chip (RCP-Chip), capable of detecting diseases in under 10 minutes. This innovation is a game-changer for fast, affordable, and portable disease screening without the need for complex lab equipment or trained personnel. Addressing the Global Need for Rapid Testing The RCP-Chip was conceived during the early days of the COVID-19 pandemic, when the world was grappling with a shortage of efficient testing methods, particularly in areas with limited resources. "Our goal was to create something fast, affordable, and easy to use, especially in areas where lab access is limited," said Mohammad A. Qasaimeh, Associate Professor of Mechanical Engineering and Bioengineering at NYUAD. Qasaimeh is the senior author of the study that led to the development of the RCP-Chip. The new tool offers a simple and rapid solution for detecting infectious diseases. "It uses a minimal number of reagents and requires only a small sample to run," Qasaimeh added, emphasizing the affordability and efficiency of the device. This paper-based diagnostic chip can be deployed easily in diverse settings, from remote villages to urban areas, and can significantly improve healthcare access. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Memperdagangkan CFD Emas dengan salah satu spread terendah? IC Markets Mendaftar Undo A Versatile Diagnostic Tool While the RCP-Chip was originally designed to detect COVID-19, its capabilities extend far beyond the novel coronavirus. According to Qasaimeh, the device is easily reconfigurable to diagnose other diseases such as chickenpox, dengue, malaria, and more. "With minor modifications, it can be adapted to diagnose a wide range of diseases or even test hormones and metabolites," Qasaimeh explained. This flexibility positions the RCP-Chip as a multi-purpose diagnostic tool that could be used in various medical fields, from general infectious disease testing to monitoring chronic health conditions. "What makes it truly impactful is its real-world potential," said Pavithra Sukumar, a Research Assistant at NYUAD and the co-first author of the study. Sukumar highlighted the tool's capacity to significantly improve outbreak responses, enabling faster isolation, treatment, and control. In situations where time is of the essence, such as in epidemic or pandemic scenarios, the rapid testing offered by the RCP-Chip can help curb the spread of diseases before they become uncontrollable. Simple, Cost-Effective, and Portable One of the standout features of the RCP-Chip is its portability. Unlike traditional diagnostic devices that require sophisticated lab setups, the chip can be operated with minimal resources. "It requires a heating stage at around 60 degrees Celsius, which can be easily achieved with common household devices like a hot plate or an oven," Qasaimeh explained. The simplicity of the design allows for easy transport and deployment, ensuring that healthcare workers in areas with limited infrastructure can use it effectively. Moreover, the RCP-Chip uses saliva samples instead of traditional swabs, making it even more convenient and comfortable for patients. "In a short amount of time, you can deploy it for use in almost any area," Qasaimeh said. This feature was a key motivation behind the development of the tool, aiming to reduce the time and cost typically associated with traditional diagnostic methods. From Concept to Commercialization The development of the RCP-Chip was not without its challenges. Due to pandemic-related lab access restrictions, the team faced delays during the initial stages of research. "In the initial phase, we focused on designing the chip and brainstorming the approaches," said Qasaimeh. It wasn't until restrictions were eased that the team was able to conduct in-depth testing of the device. "After initial curfews, gradually we were allowed access to labs, and that's when we deepened the research and began testing the device," he explained. Despite these challenges, the team successfully filed a patent for the device and launched a startup to commercialize it. Biotech companies have already expressed interest in the innovation. "We aim to find investors so that we can continue with the development stage of the device," Qasaimeh added. The focus now is on bringing the device to market and further developing its translational potential, ensuring that it can be adapted for various purposes in the healthcare sector. With the growing demand for affordable and effective diagnostic tools, the RCP-Chip is poised to play a pivotal role in global healthcare. Its low cost, speed, and versatility make it an ideal solution for resource-limited settings, providing a much-needed alternative to current testing methods.
